VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Incorporating CELMoDs into the induction & maintenance therapy of patients with multiple myeloma

Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, comments on the possibility of replacing lenalidomide with iberdomide or mezigdomide in the induction and maintenance therapy of patients with multiple myeloma to improve the efficacy of these strategies and to increase the duration of therapy to eventually improve patient outcomes. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter